CORDIS
EU research results

CORDIS

English EN

News

Cerebrospinal upregulation of BDNF and NGF expression: A novel treatment for Neuro-Endocrinal Damage originated from Paralysis & Autoimmune Diseases

A novel Nutraceutical Formulation with simultenaous BDNF and NGF mRNA expression enhancement properties may provide significant relief to neuromuscular and Neuro-endocrinal functional defects. In spite of current therapies that merely suppress related symptoms, this novel approach and ongoing / emerging protocols alike may facilitate a permanent solution for such ailments.

© Erdal Can Alkoclar & Metehan Yesil

A COMPOSITION FOR THE TREATMENT OF NEUROENDOCRINAL DAMAGE CAUSED BY AUTOIMMUNE DISEASES Technical Field The invention relates to a composition comprising dioscin derivatives and 98-E, eurycoma longifolia and cissus extracts for treating the neuroendocrinal damage caused by the autoimmune diseases. State of the Art Autoimmunity is the general name for the reactions that develop due to the hypersensitivity of the immune system. In the case of autoimmunity, the immune system mistakenly detects the body’s own constituent tissues as “intruding matter”, fails to recognize these tissues and produces antibodies against them; hence the immune system cells attack the body’s own constituent tissues. In addition, nearly all the autoimmune diseases, although not high in number, are of the idiopathic nature; in other words, their causes have not been fully understood. The corticosteroids are employed in the treatment of the autoimmune diseases as a general rule. Some of the autoimmune diseases widely known at the present may be listed as follows: Systemic lupus erythematosus (SLE), sarcoidosis, idiopathic pulmonary fibrosis, behcet’s disease, canine myositis eosinophilica, hypogammaglobulinemia, meniere syndrome, juvenile rheumatoid arthritis, kawasaki disease, wilson syndrome, multiple sclerosis, ankylosing spondylitis. Currently, the definitive treatment is not still possible for the autoimmune diseases. There is the hope that the definitive treatment may be obtained for the autoimmune diseases by the use of the stem cells. The studies are under way on the destruction of the T cells that detect the own cells of a body as the intruding matter and the transplantation of the blood stem cells producing the normal healthy T cells to replace the destroyed cells. The blood stem cells obtained from the individual’s own bone marrow may be grown in cultures and the T and B cells may be obtained from these. When administered back to the patient, these cells do not attack the body’s own cells any more. Another treatment method employed according to the state of the art involves the control and suppression of the genetic mechanism in the cells of the immune system. The cells of the immune system secrete various molecules when they are activated. The synthesis of these molecules is under the control of some genes. It is expected to alter the genetic structure in the stem cells to be able to take these genes under control. In this way, the secretion of the substances harming the body would be prevented. These genetically engineered stem cells, when administered back to the patient, produce normal T and B cells that do not harm the body’s own cells. Invention no. EP1933869B1 entitled "Use of IL-23 and IL-17 antagonists for treating the autoimmune inflammatory eye disease" deals with the novel methods and drug products involving the administration of the substances, which antagonize one or both of the activity of IL-23 and IL-17 in order to treat the autoimmune inflammatory eye disease. Further, the invention no. EP1951687B1 entitled "N-Hydroxyamide derivatives and the use thereof" relates to the N-hydroxyamide derivatives, their pharmaceutical composition, the methods for the preparation of the same and the use thereof for the treatment and/or prophylaxis of the autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis. The invention relates specifically to N-hydroxyamide derivatives for the modulation, particularly the inhibition of the activity or function of the matrix metalloprotein. As result, the presence of the need for a composition for treating the neuroendocrinal damage caused by the autoimmune diseases and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art. In the second part we will be providing extensive detail regarding the curative capacity & the curative capability of the formula.

Contributor

Contributed by:

Mas Pharmaceuticals

Turkey